Free Trial

Catalyst Pharmaceuticals (CPRX) Competitors

Catalyst Pharmaceuticals logo
$20.55 +0.02 (+0.10%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$20.72 +0.17 (+0.83%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CPRX vs. ELAN, VRNA, RVMD, RGC, ABVX, MRUS, RNA, CYTK, RYTM, and GRFS

Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Regencell Bioscience (RGC), Abivax (ABVX), Merus (MRUS), Avidity Biosciences (RNA), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

Catalyst Pharmaceuticals vs. Its Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Catalyst Pharmaceuticals currently has a consensus target price of $33.20, suggesting a potential upside of 61.56%. Elanco Animal Health has a consensus target price of $19.14, suggesting a potential downside of 10.65%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Pharmaceuticals is more favorable than Elanco Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00
Elanco Animal Health
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.91

In the previous week, Elanco Animal Health had 8 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 9 mentions for Elanco Animal Health and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.17 beat Elanco Animal Health's score of 0.64 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Catalyst Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Elanco Animal Health
3 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Catalyst Pharmaceuticals has a net margin of 37.36% compared to Elanco Animal Health's net margin of 9.68%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Elanco Animal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Catalyst Pharmaceuticals37.36% 40.78% 35.36%
Elanco Animal Health 9.68%7.04%3.45%

Catalyst Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.

Elanco Animal Health has higher revenue and earnings than Catalyst Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Pharmaceuticals$558.50M4.50$163.89M$1.6512.45
Elanco Animal Health$4.44B2.40$338M$0.8624.91

Summary

Catalyst Pharmaceuticals beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

Get Catalyst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPRX vs. The Competition

MetricCatalyst PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.52B$2.97B$6.20B$10.55B
Dividend YieldN/A54.19%5.70%4.81%
P/E Ratio12.4523.3185.7027.13
Price / Sales4.50764.66614.88134.09
Price / Cash8.40169.4137.1060.81
Price / Book3.375.3212.236.52
Net Income$163.89M$33.06M$3.33B$276.93M
7 Day Performance0.93%2.29%1.17%1.93%
1 Month Performance3.89%7.35%6.85%2.19%
1 Year Performance-3.25%-5.13%58.93%34.62%

Catalyst Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CPRX
Catalyst Pharmaceuticals
4.8287 of 5 stars
$20.55
+0.1%
$33.20
+61.6%
-3.2%$2.52B$558.50M12.4580Positive News
ELAN
Elanco Animal Health
2.576 of 5 stars
$20.04
+1.4%
$19.14
-4.5%
+65.2%$9.96B$4.48B23.309,000News Coverage
Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
1.5463 of 5 stars
$106.91
flat
$109.00
+2.0%
N/A$9.21B$42.28M-107.9930Positive News
RVMD
Revolution Medicines
4.412 of 5 stars
$48.75
+1.1%
$74.64
+53.1%
+7.3%$9.11BN/A-10.83250News Coverage
Analyst Forecast
Insider Trade
Gap Up
RGC
Regencell Bioscience
0.3975 of 5 stars
$17.99
+7.0%
N/AN/A$8.90BN/A0.0010News Coverage
ABVX
Abivax
3.4891 of 5 stars
$95.63
+2.0%
$114.25
+19.5%
+787.4%$7.23BN/A0.0061Short Interest ↓
MRUS
Merus
1.3934 of 5 stars
$94.85
+0.5%
$93.12
-1.8%
+80.1%$7.17B$56.23M-17.2537Short Interest ↓
RNA
Avidity Biosciences
2.548 of 5 stars
$48.96
-1.6%
$68.32
+39.5%
-5.1%$7.14B$10.90M-13.75190News Coverage
Insider Trade
CYTK
Cytokinetics
3.8465 of 5 stars
$59.59
-0.7%
$76.64
+28.6%
+6.3%$7.13B$85.74M-11.68250Trending News
Insider Trade
RYTM
Rhythm Pharmaceuticals
2.8746 of 5 stars
$100.77
0.0%
$106.64
+5.8%
+116.9%$6.69B$156.29M-33.48140News Coverage
Analyst Forecast
GRFS
Grifols
3.7488 of 5 stars
$9.45
+1.4%
$10.30
+9.0%
+11.6%$6.50B$7.81B8.0823,822

Related Companies and Tools


This page (NASDAQ:CPRX) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners